Circulating Myeloid-Derived Suppressor Cells Predict Favorable Response to Immune checkpoint therapy in a Randomized Trial of Nivolumab and Bevacizumab in Recurrent GBM

Manmeet Ahluwalia

Circulating Myeloid-Derived Suppressor Cells Predict Favorable Response to Immune checkpoint therapy in a Randomized Trial of Nivolumab and Bevacizumab in Recurrent GBM

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 2019
Event	Society for NeuroOncology Annual Meeting - Duration: Nov 1 2019 → …

Conference

Conference	Society for NeuroOncology Annual Meeting
Period	11/1/19 → …

Disciplines

Medicine and Health Sciences

Cite this

@conference{1d5619fcc6f04cf4aa0da5967728ff20,

title = "Circulating Myeloid-Derived Suppressor Cells Predict Favorable Response to Immune checkpoint therapy in a Randomized Trial of Nivolumab and Bevacizumab in Recurrent GBM",

author = "Manmeet Ahluwalia",

year = "2019",

month = nov,

language = "American English",

note = "Society for NeuroOncology Annual Meeting ; Conference date: 01-11-2019",

}